Perspective Therapeutics (CATX) vs Standard BioTools (LAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Perspective Therapeutics (CATX) has outperformed Standard BioTools (LAB) over the past year, losing 29.1% versus a loss of 47.8%. Over five years, CATX leads with a -60.3% price change compared with -87.3% for LAB. Perspective Therapeutics is the larger company by market cap ($277.8 million vs $256.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | LAB |
|---|---|---|
| Share price | $2.43 | $0.6527 |
| Market cap | $277.85M | $256.24M |
| 1-day change | -1.06% | -3.83% |
| YTD return | -10.55% | -46.98% |
| 1-year return | -29.11% | -47.79% |
| 5-year return | -60.32% | -87.29% |
| EPS (TTM) | $-1.33 | $-0.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $1.72 |
| 52-week low | $1.96 | $0.63 |
| Distance from 52-week high | -60.49% | -62.05% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +404.93% | +106.83% |
| Average volume | 1.67M | 1.57M |
| Shares outstanding | 114.15M | 392.58M |
| Employees | 163 | 385 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CATX has outperformed LAB by 18.7 percentage points over the past year.
- The two companies sit in different sectors: Perspective Therapeutics in Health Care and Standard BioTools in Industrials.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Standard BioTools
LAB stock →Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments.
Industrials · Biotechnology: Laboratory Analytical Instruments · 385 employees
CATX vs LAB FAQ
Which is bigger, Perspective Therapeutics or Standard BioTools?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $277.85M compared with $256.24M for Standard BioTools (LAB).
Which stock has performed better over the past year, CATX or LAB?
CATX returned -29.11% over the past 12 months, compared with -47.79% for LAB (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Standard BioTools in the same industry?
No. Perspective Therapeutics is in the Health Care sector, while Standard BioTools is in Industrials.